Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11145160rdf:typepubmed:Citationlld:pubmed
pubmed-article:11145160lifeskim:mentionsumls-concept:C2936516lld:lifeskim
pubmed-article:11145160lifeskim:mentionsumls-concept:C0220781lld:lifeskim
pubmed-article:11145160lifeskim:mentionsumls-concept:C0220825lld:lifeskim
pubmed-article:11145160lifeskim:mentionsumls-concept:C1883254lld:lifeskim
pubmed-article:11145160lifeskim:mentionsumls-concept:C0679622lld:lifeskim
pubmed-article:11145160lifeskim:mentionsumls-concept:C0205314lld:lifeskim
pubmed-article:11145160lifeskim:mentionsumls-concept:C0243072lld:lifeskim
pubmed-article:11145160pubmed:issue12lld:pubmed
pubmed-article:11145160pubmed:dateCreated2000-12-28lld:pubmed
pubmed-article:11145160pubmed:abstractTextA series of N-azabicycloalkyl-1-alkyl-2-oxo-1,2-dihydro-3-quinolinecarboxamides were synthesized and tested for serotonin 5-HT4 receptor-stimulating effects in the regulation of electrically-evoked contraction in guinea pig muscle. Among them, N-azabicycloalkyl-1-isopropyl-2-oxo-1,2-dihydro-3-quinolinecarboxamide (8c, 9c, 10c, 11c, 12c) exhibited potent serotonin 5-HT4 receptor-stimulating activity. The most potent compound, N-(endo-8-methyl-8-azabicyclo[3.2.1 oct-3-yl)-1-isopropyl-2-oxo-1,2-dihydro-3-quinolinecarboxamide (8c, ED50 = 36.3 nMi), was seven times as active as cisapride, while 8c had no affinity for 5-HT1A, 5-HT1D, D2, muscarinic M2 or muscarinic M3 receptors even at 10 microM. Compound 8c stimulated digestive tract motility in conscious fed dogs (1.0 mg/kg p.o.).lld:pubmed
pubmed-article:11145160pubmed:languageenglld:pubmed
pubmed-article:11145160pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11145160pubmed:citationSubsetIMlld:pubmed
pubmed-article:11145160pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11145160pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11145160pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11145160pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11145160pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11145160pubmed:statusMEDLINElld:pubmed
pubmed-article:11145160pubmed:monthDeclld:pubmed
pubmed-article:11145160pubmed:issn0009-2363lld:pubmed
pubmed-article:11145160pubmed:authorpubmed-author:SuzukiMMlld:pubmed
pubmed-article:11145160pubmed:authorpubmed-author:KanekoTTlld:pubmed
pubmed-article:11145160pubmed:authorpubmed-author:MuramatsuMMlld:pubmed
pubmed-article:11145160pubmed:authorpubmed-author:ItoCClld:pubmed
pubmed-article:11145160pubmed:authorpubmed-author:AsanumaHHlld:pubmed
pubmed-article:11145160pubmed:authorpubmed-author:IsobeYYlld:pubmed
pubmed-article:11145160pubmed:authorpubmed-author:YokomoriSSlld:pubmed
pubmed-article:11145160pubmed:authorpubmed-author:OhuchiYYlld:pubmed
pubmed-article:11145160pubmed:issnTypePrintlld:pubmed
pubmed-article:11145160pubmed:volume48lld:pubmed
pubmed-article:11145160pubmed:ownerNLMlld:pubmed
pubmed-article:11145160pubmed:authorsCompleteYlld:pubmed
pubmed-article:11145160pubmed:pagination2003-8lld:pubmed
pubmed-article:11145160pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:11145160pubmed:meshHeadingpubmed-meshheading:11145160...lld:pubmed
pubmed-article:11145160pubmed:meshHeadingpubmed-meshheading:11145160...lld:pubmed
pubmed-article:11145160pubmed:meshHeadingpubmed-meshheading:11145160...lld:pubmed
pubmed-article:11145160pubmed:meshHeadingpubmed-meshheading:11145160...lld:pubmed
pubmed-article:11145160pubmed:meshHeadingpubmed-meshheading:11145160...lld:pubmed
pubmed-article:11145160pubmed:meshHeadingpubmed-meshheading:11145160...lld:pubmed
pubmed-article:11145160pubmed:meshHeadingpubmed-meshheading:11145160...lld:pubmed
pubmed-article:11145160pubmed:meshHeadingpubmed-meshheading:11145160...lld:pubmed
pubmed-article:11145160pubmed:meshHeadingpubmed-meshheading:11145160...lld:pubmed
pubmed-article:11145160pubmed:meshHeadingpubmed-meshheading:11145160...lld:pubmed
pubmed-article:11145160pubmed:meshHeadingpubmed-meshheading:11145160...lld:pubmed
pubmed-article:11145160pubmed:meshHeadingpubmed-meshheading:11145160...lld:pubmed
pubmed-article:11145160pubmed:meshHeadingpubmed-meshheading:11145160...lld:pubmed
pubmed-article:11145160pubmed:year2000lld:pubmed
pubmed-article:11145160pubmed:articleTitleSynthesis and evaluation of novel 2-oxo-1,2-dihydro-3-quinolinecarboxamide derivatives as serotonin 5-HT4 receptor agonists.lld:pubmed
pubmed-article:11145160pubmed:affiliationResearch Center, Taisho Pharmaceutical Co, Ltd, Ohmiya, Saitama, Japan. s13845@ccm.taisho.co.jplld:pubmed
pubmed-article:11145160pubmed:publicationTypeJournal Articlelld:pubmed